Provided by Tiger Trade Technology Pte. Ltd.

Vera Therapeutics, Inc.

41.76
-0.3900-0.93%
Post-market: 41.760.00000.00%17:26 EST
Volume:882.64K
Turnover:36.65M
Market Cap:2.93B
PE:-10.44
High:42.51
Open:41.78
Low:40.32
Close:42.15
52wk High:56.05
52wk Low:18.53
Shares:70.07M
Float Shares:50.20M
Volume Ratio:0.85
T/O Rate:1.76%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.9990
EPS(LYR):-2.7500
ROE:-73.25%
ROA:-38.12%
PB:7.34
PE(LYR):-15.19

Loading ...

Evercore ISI Sticks to Its Buy Rating for Vera Therapeutics (VERA)

TIPRANKS
·
Feb 17

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Feb 07

Vera Therapeutics Files Initial Beneficial Ownership Statement for Chief Commercial Officer Laurence Matthew Skelton

Reuters
·
Jan 31

Press Release: Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer

Dow Jones
·
Jan 28

Assessing Vera Therapeutics (VERA) Valuation After Phase Three Success And AI Drug Discovery Progress

Simply Wall St.
·
Jan 27

Vera Therapeutics Grants Stock Options and RSUs to New Employees Under 2024 Inducement Plan

Reuters
·
Jan 10

BUZZ-U.S. STOCKS ON THE MOVE-Nvidia, Boeing, Lowe's

Reuters
·
Jan 08

BUZZ-U.S. STOCKS ON THE MOVE-Hershey, Praxis Precision, Cal-Maine Foods

Reuters
·
Jan 07

BUZZ-Vera soars as FDA accepts priority review for kidney disease drug

Reuters
·
Jan 07

Vera Therapeutics Shares up 14.4% Premarket After Co Receives U.S. FDA Priority Review for Kidney Disease Drug

THOMSON REUTERS
·
Jan 07

BRIEF-Vera Therapeutics Announces U.S. FDA Granted Priority Review To Biologics License Application

Reuters
·
Jan 07

FDA Grants Priority Review to Vera Therapeutics' Atacicept for IgA Nephropathy

Reuters
·
Jan 07

Vera Therapeutics Inc - Atacicept Receives FDA Breakthrough Therapy Designation for Igan

THOMSON REUTERS
·
Jan 07

Vera Therapeutics Inc: FDA Assigned Pdufa Target Action Date of July 7, 2026.

THOMSON REUTERS
·
Jan 07

Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults With Iga Nephropathy

THOMSON REUTERS
·
Jan 07

Vera Therapeutics Inc: FDA Assigned Pdufa Target Action Date of July 7, 2026.

THOMSON REUTERS
·
Jan 07

Vera Therapeutics (VERA): Reassessing Valuation After Analyst Upgrades and Cash Boost for Atacicept Launch Prospects

Simply Wall St.
·
Dec 23, 2025

Vera Therapeutics Is Maintained at Buy by B of A Securities

Dow Jones
·
Dec 20, 2025

Vera Therapeutics Is Maintained at Overweight by JP Morgan

Dow Jones
·
Dec 20, 2025

Vera Therapeutics Inc : Bofa Global Research Raises Price Objective to $66.00 From $48.00

THOMSON REUTERS
·
Dec 19, 2025